Novel pharmacological modulators of autophagy: an updated patent review (2012-2015)

Expert Opinion on Therapeutic Patents

Volumn 26, Issue 11, 2016, Pages 1273-1289

  Ha, Joohun ^a   Kim, Joungmok ^b  

^a Kyung Hee University Hospital   (South Korea)

^b Kyung Hee University   (South Korea)

Author keywords

AMPK mTORC1; Autophagy; autophagy modulators; Beclin 1; cancer; neurodegenerative diseases; PIK3C3 VPS34; ULK1

Indexed keywords

6 CHLORO 2 METHOXY N (4 (4 METHYLPIPERAZIN 1 YL)BUTYL)ACRIDIN 9 AMINE; ALKALOID DERIVATIVE; AUTOPHAGY INHIBITOR; BUTYLIDENEPHTHALIDE; ELLAGIC ACID; GANODERIC ACID; INDATRALINE; INDOLE DERIVATIVE; LUCANTHONE; NATURAL PRODUCT; OBLONGIFOLIN C; OXINDOLE; PHENYLBUTYRATE; RECEPTOR BLOCKING AGENT; RETINOIC ACID RECEPTOR ALPHA ANTAGONIST; UNCLASSIFIED DRUG; UROLITHIN DERIVATIVE;

AUTOPHAGY; CELL ENERGY; CLINICAL EVALUATION; DRUG DESIGN; HUMAN; METABOLISM; NEOPLASM; NERVE DEGENERATION; NONHUMAN; PATENT; PROTEIN TARGETING; REVIEW; AGING; ANIMAL; DIABETES MELLITUS; DRUG EFFECTS; HOMEOSTASIS; LYSOSOME; NEOPLASMS; NEURODEGENERATIVE DISEASES; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

AGING; ANIMALS; AUTOPHAGY; DIABETES MELLITUS; DRUG DESIGN; HOMEOSTASIS; HUMANS; LYSOSOMES; NEOPLASMS; NEURODEGENERATIVE DISEASES; PATENTS AS TOPIC;

EID: 84992046814     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1080/13543776.2016.1217996     Document Type: Review

References (158)

1. P.Boya, F.Reggiori, P.Codogno Emerging regulation and functions of autophagy. Nat Cell Biol. 2013 Jul;15(7):713–720.
2. S.Sridhar, Y.Botbol, F.Macian, et al. Autophagy and disease:always two sides to a problem. J Pathol. 2012 Jan;226(2):255–273.• This review shows a number of studies demonstrating that autophagy has both beneficial and detrimental effects on the development and progression of human diseases.
3. R.Singh, A.M.Cuervo. Autophagy in the cellular energetic balance. Cell Metab. 2011 May 4;13(5):495–504.
4. V.Deretic, B.Levine. Autophagy, immunity, and microbial adaptations. Cell Host Microbe. 2009 Jun 18;5(6):527–549.
5. N.Mizushima, B.Levine, A.M.Cuervo, et al. Autophagy fights disease through cellular self-digestion. Nature. 2008 Feb 28;451(7182):1069–1075.
6. B.Levine, G.Kroemer. Autophagy in the pathogenesis of disease. Cell. 2008 Jan 11;132(1):27–42.
7. S.Kaushik, A.M.Cuervo. Chaperone-mediated autophagy:a unique way to enter the lysosome world. Trends Cell Biol. 2012 Aug;22(8):407–417.
8. L.Lv, D.Li, D.Zhao, et al. Acetylation targets the M2 isoform of pyruvate kinase for degradation through chaperone-mediated autophagy and promotes tumor growth. Mol Cell. 2011 Jun 24;42(6):719–730.
9. L.M.Thompson, C.T.Aiken, L.S.Kaltenbach, et al. IKK phosphorylates Huntingtin and targets it for degradation by the proteasome and lysosome. J Cell Biol. 2009 Dec 28;187(7):1083–1099.
10. M.Kon, R.Kiffin, H.Koga, et al. Chaperone-mediated autophagy is required for tumor growth. Sci Transl Med. 2011 Nov 16;3(109):109ra17.
11. D.C.Rubinsztein, T.Shpilka, Z.Elazar. Mechanisms of autophagosome biogenesis. Curr Biol. 2012 Jan 10;22(1):R29–34.
12. N.Mizushima, T.Yoshimori, Y.Ohsumi. The role of Atg proteins in autophagosome formation. Annu Rev Cell Dev Biol. 2011;27:107–132.• This review describes the molecular mechanism of autophagosome formation with particular focus on the coordinated actions of autophagy machinery ATG proteins and the long-standing discussion regarding the origin of the autophagosome membrane.
13. H.Popelka, D.J.Klionsky. Post-translationally-modified structures in the autophagy machinery:an integrative perspective. Febs J. 2015 Sep;282(18):3474–3488.
14. D.Denton, S.Nicolson, S.Kumar. Cell death by autophagy:facts and apparent artefacts. Cell Death Differ. 2012 Jan;19(1):87–95.• Although there is growing evidence of cell death by autophagy, autophagic cell death remains somewhat controversial. This review introduces growing number of studies supporting that autophagy play a clear role in cell death process and discusses the potential significance of cell death by autophagy.
15. A.Fleming, T.Noda, T.Yoshimori, et al. Chemical modulators of autophagy as biological probes and potential therapeutics. Nat Chem Biol. 2011 Jan;7(1):9–17.
16. P.Bischoff, E.Josset, F.J.Dumont. Novel pharmacological modulators of autophagy and therapeutic prospects. Expert Opin Ther Pat. 2012 Sep;22(9):1053–1079.• It is a review demonstrating the patent applications published from 2008 to mid-2012 that pertain to the pharmacological modulation of autophagy. This review also discussed their potential therapeutic utilities.
17. B.Ravikumar, S.Sarkar, J.E.Davies, et al. Regulation of mammalian autophagy in physiology and pathophysiology. Physiol Rev. 2010 Oct;90(4):1383–1435.• It is a comprehensive review providing an overview of the autophagic machinery and its mechanisms of regulation under normal physiological conditions. It also introduces a number of studies showing malfunction (dysregulation) of autophagy is associated with a variety of human pathophysiological conditions.
18. G.Kroemer. Autophagy:a druggable process that is deregulated in aging and human disease. J Clin Invest. 2015 Jan;125(1):1–4.• This article summarizes numerous attempts to identify specific inducers or inhibitors of autophagy and to use them for the therapeutic correction of its dysregulation or malfunction. It also provides promising preclinical results and several clinical trials exploring autophagy as a therapeutic target.
19. D.C.Rubinsztein, P.Codogno, B.Levine. Autophagy modulation as a potential therapeutic target for diverse diseases. Nat Rev Drug Discov. 2012 Sep;11(9):709–730.
20. D.C.Rubinsztein, G.Marino, G.Kroemer. Autophagy and aging. Cell. 2011 Sep 2;146(5):682–695.
21. F.Janku, D.J.McConkey, D.S.Hong, et al. Autophagy as a target for anticancer therapy. Nat Rev Clin Oncol. 2011 Sep;8(9):528–539.•• It reviews the lines of evidence that autophagy can both suppress cancer development at an early stage and promote tumor progression by enabling cancer cells to survive in stressful cancer microenvironments. It also demonstrates the molecular connections between autophagy and cancer biology for the therapeutic purpose.
22. L.Galluzzi, F.Pietrocola, B.Levine, et al. Metabolic control of autophagy. Cell. 2014 Dec 4;159(6):1263–1276.•• It is an excellent review providing comprehensive information about the physiological regulation of autophagy by metabolic circuitries as well as alterations of such control in diseases.
23. X.Jiang, M.Overholtzer, C.B.Thompson. Autophagy in cellular metabolism and cancer. J Clin Invest. 2015 Jan;125(1):47–54.•• In this review, the role of autophagy in both regular and disease conditions is discussed, especially at the level of ULK1 connecting the nutrient signaling pathways. Importantly, the role of autophagy in cancer and its potential as a cancer therapeutic target are considered.
24. J.Ha, K.L.Guan, J.Kim. AMPK and autophagy in glucose/glycogen metabolism. Mol Aspects Med. 2015 Dec;46:46–62.
25. M.Komatsu, S.Waguri, T.Ueno, et al. Impairment of starvation-induced and constitutive autophagy in Atg7-deficient mice. J Cell Biol. 2005 May 9;169(3):425–434.
26. A.Kuma, M.Hatano, M.Matsui, et al. The role of autophagy during the early neonatal starvation period. Nature. 2004 Dec 23;432(7020):1032–1036.
27. R.Singh, S.Kaushik, Y.Wang, et al. Autophagy regulates lipid metabolism. Nature. 2009 Apr 30;458(7242):1131–1135.
28. H.S.Jung, K.W.Chung, J.Won Kim, et al. Loss of autophagy diminishes pancreatic beta cell mass and function with resultant hyperglycemia. Cell Metab. 2008 Oct;8(4):318–324.
29. C.Ebato, T.Uchida, M.Arakawa, et al. Autophagy is important in islet homeostasis and compensatory increase of beta cell mass in response to high-fat diet. Cell Metab. 2008 Oct;8(4):325–332.
30. L.Yang, P.Li, S.Fu, et al. Defective hepatic autophagy in obesity promotes ER stress and causes insulin resistance. Cell Metab. 2010 Jun 9;11(6):467–478.
31. Y.Fujitani, R.Kawamori, H.Watada. The role of autophagy in pancreatic beta-cell and diabetes. Autophagy. 2009 Feb;5(2):280–282.
32. M.T.Rosenfeldt, K.M.Ryan. The role of autophagy in tumour development and cancer therapy. Expert Rev Mol Med. 2009;11:e36.• This review provides the lines of evidence showing that oncogenes and tumor suppressor genes regulate autophagy. Also, the potential of autophagy as a therapeutic target is discussed in light of the functions of autophagy at different stages of tumor progression and in normal tissues.
33. J.M.Levy, A.Thorburn. Targeting autophagy during cancer therapy to improve clinical outcomes. Pharmacol Ther. 2011 Jul;131(1):130–141.
34. X.H.Liang, S.Jackson, M.Seaman, et al. Induction of autophagy and inhibition of tumorigenesis by beclin 1. Nature. 1999 Dec 9;402(6762):672–676.• It is a first report demonstrating that the autophagy machinery, Beclin-1, can function as tumor suppressor. This study showed that Beclin-1 expression was frequently decreased in several human cancer cell lines and tissue. These findings provided important information that autophagy can contribute to the development or progression of tumors and other human malignancies.
35. X.Qu, J.Yu, G.Bhagat, et al. Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. J Clin Invest. 2003 Dec;112(12):1809–1820.
36. M.R.Kang, M.S.Kim, J.E.Oh, et al. Frameshift mutations of autophagy-related genes ATG2B, ATG5, ATG9B and ATG12 in gastric and colorectal cancers with microsatellite instability. J Pathol. 2009 Apr;217(5):702–706.
37. H.Knaevelsrud, T.Ahlquist, M.A.Merok, et al. UVRAG mutations associated with microsatellite unstable colon cancer do not affect autophagy. Autophagy. 2010 Oct;6(7):863–870.
38. Y.Takahashi, D.Coppola, N.Matsushita, et al. Bif-1 interacts with Beclin 1 through UVRAG and regulates autophagy and tumorigenesis. Nat Cell Biol. 2007 Oct;9(10):1142–1151.
39. S.V.Laddha, S.Ganesan, C.S.Chan, et al. Mutational landscape of the essential autophagy gene BECN1 in human cancers. Mol Cancer Res. 2014 Apr;12(4):485–490.
40. V.Karantza-Wadsworth, S.Patel, O.Kravchuk, et al. Autophagy mitigates metabolic stress and genome damage in mammary tumorigenesis. Genes Dev. 2007 Jul 1;21(13):1621–1635.
41. R.Mathew, S.Kongara, B.Beaudoin, et al. Autophagy suppresses tumor progression by limiting chromosomal instability. Genes Dev. 2007 Jun 1;21(11):1367–1381.
42. J.Moscat, M.T.Diaz-Meco. p62 at the crossroads of autophagy, apoptosis, and cancer. Cell. 2009 Jun 12;137(6):1001–1004.
43. A.Takamura, M.Komatsu, T.Hara, et al. Autophagy-deficient mice develop multiple liver tumors. Genes Dev. 2011 Apr 15;25(8):795–800.
44. A.Duran, J.F.Linares, A.S.Galvez, et al. The signaling adaptor p62 is an important NF-kappaB mediator in tumorigenesis. Cancer Cell. 2008 Apr;13(4):343–354.
45. Y.Inami, S.Waguri, A.Sakamoto, et al. Persistent activation of Nrf2 through p62 in hepatocellular carcinoma cells. J Cell Biol. 2011 Apr 18;193(2):275–284.
46. S.Y.Lunt, M.G.Vander Heiden. Aerobic glycolysis:meeting the metabolic requirements of cell proliferation. Annu Rev Cell Dev Biol. 2011;27:441–464.
47. G.L.Semenza. HIF-1:upstream and downstream of cancer metabolism. Curr Opin Genet Dev. 2010 Feb;20(1):51–56.
48. C.Frezza, L.Zheng, D.A.Tennant, et al. Metabolic profiling of hypoxic cells revealed a catabolic signature required for cell survival. PLoS One. 2011;6(9):e24411.
49. S.Pavlides, I.Vera, R.Gandara, et al. Warburg meets autophagy:cancer-associated fibroblasts accelerate tumor growth and metastasis via oxidative stress, mitophagy, and aerobic glycolysis. Antioxid Redox Signal. 2012 Jun 1;16(11):1264–1284.
50. C.Capparelli, C.Guido, D.Whitaker-Menezes, et al. Autophagy and senescence in cancer-associated fibroblasts metabolically supports tumor growth and metastasis via glycolysis and ketone production. Cell Cycle. 2012 Jun 15;11(12):2285–2302.
51. R.Lock, S.Roy, C.M.Kenific, et al. Autophagy facilitates glycolysis during Ras-mediated oncogenic transformation. Mol Biol Cell. 2011 Jan 15;22(2):165–178.
52. J.Y.Guo, H.Y.Chen, R.Mathew, et al. Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis. Genes Dev. 2011 Mar 1;25(5):460–470.•• This study showed “autophagy addiction” of cancer cells. In the cells harboring activated RAS mutations, autophagy was upregulated to maintain the pool of functional mitochondria supporting Ras-driven tumor growth. As cancers with RAS mutations have a poor prognosis, this “autophagy addiction” suggests that targeting autophagy and mitochondrial metabolism are valuable new approaches to treat these aggressive cancers.
53. S.Yang, X.Wang, G.Contino, et al. Pancreatic cancers require autophagy for tumor growth. Genes Dev. 2011 Apr 1;25(7):717–729.
54. J.Y.Guo, G.Karsli-Uzunbas, R.Mathew, et al. Autophagy suppresses progression of K-ras-induced lung tumors to oncocytomas and maintains lipid homeostasis. Genes Dev. 2013 Jul 1;27(13):1447–1461.• Along with [69], this study also demonstrates that Ras-driven tumors require autophagy for mitochondrial function and lipid catabolism. It suggests that autophagy is required for carcinoma fate, and autophagy defects may be a molecular basis for the occurrence of oncocytomas.
55. M.Komatsu, S.Waguri, T.Chiba, et al. Loss of autophagy in the central nervous system causes neurodegeneration in mice. Nature. 2006 Jun 15;441(7095):880–884.
56. T.Hara, K.Nakamura, M.Matsui, et al. Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. Nature. 2006 Jun 15;441(7095):885–889.
57. M.Martinez-Vicente, A.M.Cuervo. Autophagy and neurodegeneration:when the cleaning crew goes on strike. Lancet Neurol. 2007 Apr;6(4):352–361.
58. D.C.Rubinsztein. The roles of intracellular protein-degradation pathways in neurodegeneration. Nature. 2006 Oct 19;443(7113):780–786.
59. A.M.Cuervo, L.Stefanis, R.Fredenburg, et al. Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science. 2004 Aug 27;305(5688):1292–1295.
60. G.Bjorkoy, T.Lamark, A.Brech, et al. p62/SQSTM1 forms protein aggregates degraded by autophagy and has a protective effect on huntingtin-induced cell death. J Cell Biol. 2005 Nov 21;171(4):603–614.
61. M.Komatsu, S.Waguri, M.Koike, et al. Homeostatic levels of p62 control cytoplasmic inclusion body formation in autophagy-deficient mice. Cell. 2007 Dec 14;131(6):1149–1163.
62. W.H.Yu, A.M.Cuervo, A.Kumar, et al. Macroautophagy – a novel beta-amyloid peptide-generating pathway activated in Alzheimer’s disease. J Cell Biol. 2005 Oct 10;171(1):87–98.
63. N.T.Ktistakis, S.A.Tooze. Digesting the expanding mechanisms of autophagy. Trends Cell Biol. 2016 Aug;26(8):624–635.•• It is an up-to-date review demonstrating how autophagy machinery proteins coordinately work for autophagosome/autolysosome biogenesis. This review also deals with the recent advances on the understanding of the origin of autophagosome membrane and novel regulators. Moreover, it introduces a number of studies showing the functions of noncanonical autophagy and the role of autophagy proteins in these non-autophagy pathways.
64. D.G.Hardie, B.E.Schaffer, A.Brunet. AMPK:an energy-sensing pathway with multiple inputs and outputs. Trends Cell Biol. 2016 Mar;26(3):190–201.
65. A.Efeyan, R.Zoncu, D.M.Sabatini. Amino acids and mTORC1:from lysosomes to disease. Trends Mol Med. 2012 Sep;18(9):524–533.
66. R.Zoncu, L.Bar-Peled, A.Efeyan, et al. mTORC1 senses lysosomal amino acids through an inside-out mechanism that requires the vacuolar H(+)-ATPase. Science. 2011 Nov 4;334(6056):678–683.
67. C.S.Zhang, B.Jiang, M.Li, et al. The lysosomal v-ATPase-Ragulator complex is a common activator for AMPK and mTORC1, acting as a switch between catabolism and anabolism. Cell Metab. 2014 Sep 2;20(3):526–540.
68. Y.Kamada, T.Funakoshi, T.Shintani, et al. Tor-mediated induction of autophagy via an Apg1 protein kinase complex. J Cell Biol. 2000 Sep 18;150(6):1507–1513.
69. N.Hosokawa, T.Hara, T.Kaizuka, et al. Nutrient-dependent mTORC1 association with the ULK1-Atg13-FIP200 complex required for autophagy. Mol Biol Cell. 2009 Apr;20(7):1981–1991.
70. C.H.Jung, C.B.Jun, S.H.Ro, et al. ULK-Atg13-FIP200 complexes mediate mTOR signaling to the autophagy machinery. Mol Biol Cell. 2009 Apr;20(7):1992–2003.
71. F.Nazio, F.Strappazzon, M.Antonioli, et al. mTOR inhibits autophagy by controlling ULK1 ubiquitylation, self-association and function through AMBRA1 and TRAF6. Nat Cell Biol. 2013 Apr;15(4):406–416.
72. J.Kim, M.Kundu, B.Viollet, et al. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat Cell Biol. 2011 Feb;13(2):132–141.• This study provided the first evidence underlying AMPK–mTORC1–ULK1 triad, in which AMPK and mTORC1 cooperatively regulate ULK1 activity in response to glucose starvation.
73. D.F.Egan, D.B.Shackelford, M.M.Mihaylova, et al. Phosphorylation of ULK1 (hATG1) by AMP-activated protein kinase connects energy sensing to mitophagy. Science. 2011 Jan 28;331(6016):456–461.
74. E.A.Dunlop, D.K.Hunt, H.A.Acosta-Jaquez, et al. ULK1 inhibits mTORC1 signaling, promotes multisite Raptor phosphorylation and hinders substrate binding. Autophagy. 2011 Jul;7(7):737–747.
75. A.S.Loffler, S.Alers, A.M.Dieterle, et al. Ulk1-mediated phosphorylation of AMPK constitutes a negative regulatory feedback loop. Autophagy. 2011 Jul;7(7):696–706.
76. E.A.Dunlop, A.R.Tee. The kinase triad, AMPK, mTORC1 and ULK1, maintains energy and nutrient homoeostasis. Biochem Soc Trans. 2013 Aug;41(4):939–943.
77. J.Kim, Y.C.Kim, C.Fang, et al. Differential regulation of distinct Vps34 complexes by AMPK in nutrient stress and autophagy. Cell. 2013 Jan 17;152(1–2):290–303.• It demonstrates that AMPK oppositely regulates non- and pro-autophagy PIK3C3/VPS34 complexes by directly phosphorylating Vps34 and Beclin-1 subunits. Most importantly, this study shows that an autophagy-specific subunit, ATG14L, on pro-autophagy PIK3C3/VPS34 complex dictates the differential regulation (either inhibition or activation) of PIK3C3/VPS34 complexes mediated by AMPK.
78. R.C.Russell, Y.Tian, H.Yuan, et al. ULK1 induces autophagy by phosphorylating Beclin-1 and activating VPS34 lipid kinase. Nat Cell Biol. 2013 Jul;15(7):741–750.
79. H.X.Yuan, R.C.Russell, K.L.Guan. Regulation of PIK3C3/VPS34 complexes by MTOR in nutrient stress-induced autophagy. Autophagy. 2013 Dec;9(12):1983–1995.
80. Y.C.Kim, K.L.Guan. mTOR:a pharmacologic target for autophagy regulation. J Clin Invest. 2015 Jan;125(1):25–32.
81. M.B.Lazarus, C.J.Novotny, K.M.Shokat. Structure of the human autophagy initiating kinase ULK1 in complex with potent inhibitors. ACS Chem Biol. 2015 Jan 16;10(1):257–261.
82. M.B.Lazarus, K.M.Shokat. Discovery and structure of a new inhibitor scaffold of the autophagy initiating kinase ULK1. Bioorg Med Chem. 2015 Sep 1;23(17):5483–5488.
83. K.J.Petherick, O.J.Conway, C.Mpamhanga, et al. Pharmacological inhibition of ULK1 kinase blocks mammalian target of rapamycin (mTOR)-dependent autophagy. J Biol Chem. 2015 May 1;290(18):11376–11383.
84. D.F.Egan, M.G.Chun, M.Vamos, et al. Small molecule inhibition of the autophagy kinase ULK1 and identification of ULK1 substrates. Mol Cell. 2015 Jul 16;59(2):285–297.
85. S.Miller, B.Tavshanjian, A.Oleksy, et al. Shaping development of autophagy inhibitors with the structure of the lipid kinase Vps34. Science. 2010 Mar 26;327(5973):1638–1642.• This study shows three-dimensional structure Vps34, a catalytic subunit of PIK3C3/VPS34 complex, at 2.9 angstrom resolution. It provides the molecular background to design novel and potent PIK3C3/VPS34-specific inhibitors.
86. B.Ronan, O.Flamand, L.Vescovi, et al. A highly potent and selective Vps34 inhibitor alters vesicle trafficking and autophagy. Nat Chem Biol. 2014 Dec;10(12):1013–1019.
87. B.Pasquier, Y.El-Ahmad, B.Filoche-Romme, et al. Discovery of (2S)-8-[(3R)-3-methylmorpholin-4-yl]-1-(3-methyl-2-oxobutyl)-2-(trifluoromethyl)- 3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one:a novel potent and selective inhibitor of Vps34 for the treatment of solid tumors. J Med Chem. 2015 Jan 8;58(1):376–400.
88. R.Bago, N.Malik, M.J.Munson, et al. Characterization of VPS34-IN1, a selective inhibitor of Vps34, reveals that the phosphatidylinositol 3-phosphate-binding SGK3 protein kinase is a downstream target of class III phosphoinositide 3-kinase. Biochem J. 2014 Nov 1;463(3):413–427.
89. W.E.Dowdle, B.Nyfeler, J.Nagel, et al. Selective VPS34 inhibitor blocks autophagy and uncovers a role for NCOA4 in ferritin degradation and iron homeostasis in vivo. Nat Cell Biol. 2014 Nov;16(11):1069–1079.
90. J.M.Backer. The regulation and function of Class III PI3Ks:novel roles for Vps34. Biochem J. 2008 Feb 15;410(1):1–17.
91. J.Liu, H.Xia, M.Kim, et al. Beclin1 controls the levels of p53 by regulating the deubiquitination activity of USP10 and USP13. Cell. 2011 Sep 30;147(1):223–234.• It is an important article that describes the discovery and biological characterization of Spautin-1, a novel type of small-molecule inhibitor of autophagy promoting the proteosomal Beclin-1 degradation, as an anticancer agent.
92. S.Shao, S.Li, Y.Qin, et al. Spautin-1, a novel autophagy inhibitor, enhances imatinib-induced apoptosis in chronic myeloid leukemia. Int J Oncol. 2014 May;44(5):1661–1668.
93. E.Jabbour. Chronic myeloid leukemia:first-line drug of choice. Am J Hematol. 2016 Jan;91(1):59–66.
94. S.Shoji-Kawata, R.Sumpter, M.Leveno, et al. Identification of a candidate therapeutic autophagy-inducing peptide. Nature. 2013 Feb 14;494(7436):201–206.
95. M.R.Slobodkin, Z.Elazar. The Atg8 family:multifunctional ubiquitin-like key regulators of autophagy. Essays Biochem. 2013;55:51–64.
96. D.Akin, S.K.Wang, P.Habibzadegah-Tari, et al. A novel ATG4B antagonist inhibits autophagy and has a negative impact on osteosarcoma tumors. Autophagy. 2014;10(11):2021–2035.
97. D.Xu, Z.Xu, L.Han, et al. Identification of new ATG4B inhibitors based on a novel high-throughput screening platform. J Biomol Screen. 2016 Mar 18. pii:1087057116639202. [Epub ahead of print].
98. J.S.Lee, Q.Li, J.Y.Lee, et al. FLIP-mediated autophagy regulation in cell death control. Nat Cell Biol. 2009 Nov;11(11):1355–1362.
99. P.Garcia-Valtanen, M.Ortega-Villaizan Mdel, A.Martinez-Lopez, et al. Autophagy-inducing peptides from mammalian VSV and fish VHSV rhabdoviral G glycoproteins (G) as models for the development of new therapeutic molecules. Autophagy. 2014 Sep;10(9):1666–1680.
100. Macau University of Science and Technology, Macau, CN. Novel autophagy enhancer for treatment of neurodegenerative diseases.US20150050363A1. 2015.
101. Macau University of Science and Technology, Macau, CN. Group of alkaloids, the novel autophagy enhancers for treatment of cancers and neurodegenerative conditions thereof.US20150190392A1. 2015.
102. Macau University of Science and Technology, Macau, CN. N-desmethyldauricine, A novel autophagic enhancer for treatment of cancers and neurodegenerative conditions thereof.US20150133492A1. 2015.
103. Albert Einstein College of Medicine of Yeshiva University, NY, US. Retinoic acid receptor antagonists as chaperone-mediated autophagy modulators and uses thereof.US20150166492A1. 2015.
104. University of Southern California, Los Angeles, CA, US. Phenylbutyrate for treatment of sporadic inclusion-body myositis and disorders relating to autophagy impairment of amyloid beta 42 accumulation.US20140206763A1. 2014.
105. National Yang-Ming University, Taipei, TW. Method and composition for inducing autophagy.US20140147464A1. 2014.
106. Amazentis SA,Ecublens, CH. Enhancing autophagy or increasing longevity by administration of urolithins or precursors thereof.US20140018415A1. 2014.
107. K.H.Jeong, C.Y.Sun. Pharmaceutical composition for preventing or treating autophagy-related diseases, angiogenic diseases or melanin-related disease.US20130251654A1. 2013.
108. Hong Kong Baptist University, Hong Kong, HK. Autophagy inducing compound and the uses thereof.US20120245190A1. 2012.
109. Board of Regents, The University of Texas System, US. Autophagy-inducing peptide.WO2013119377A1. 2013.
110. Board of Regents, The University of Texas System, US. Autophagy-inducing peptide analogs.WO2014149440A1. 2014.
111. Y.Liu, Y.Xu, W.Ji, et al. Anti-tumor activities of matrine and oxymatrine:literature review. Tumour Biol. 2014 Jun;35(6):5111–5119.
112. N.Wang, Y.Feng, M.Zhu, et al. Berberine induces autophagic cell death and mitochondrial apoptosis in liver cancer cells:the cellular mechanism. J Cell Biochem. 2010 Dec 15;111(6):1426–1436.
113. J.H.Lu, J.Q.Tan, S.S.Durairajan, et al. Isorhynchophylline, a natural alkaloid, promotes the degradation of alpha-synuclein in neuronal cells via inducing autophagy. Autophagy. 2012 Jan;8(1):98–108.
114. S.K.Kulkarni, A.Dhir. Berberine:a plant alkaloid with therapeutic potential for central nervous system disorders. Phytother Res. 2010 Mar;24(3):317–324.
115. F.A.Urra, M.Cordova-Delgado, H.Pessoa-Mahana, et al. Mitochondria:a promising target for anticancer alkaloids. Curr Top Med Chem. 2013 Sep;13(17):2171–2183.
116. X.Liu, S.Huang, X.Wang, et al. Chaperone-mediated autophagy and neurodegeneration:connections, mechanisms, and therapeutic implications. Neurosci Bull. 2015 Aug;31(4):407–415.
117. I.Tasset, A.M.Cuervo. Role of chaperone-mediated autophagy in metabolism. FEBS J. 2016 Jul;283(13):2403–2413.
118. X.H.Tang, L.J.Gudas. Retinoids, retinoic acid receptors, and cancer. Annu Rev Pathol-Mech. 2011;6:345–364.
119. J.Füllgrabe, D.J.Klionsky, B.Joseph. The return of the nucleus:transcriptional and epigenetic control of autophagy. Nat Rev Mol Cell Biol. 2014 Jan;15(1):65–74.
120. Y.Rajawat, Z.Hilioti, I.Bossis. Retinoic acid induces autophagosome maturation through redistribution of the cation-independent mannose-6-phosphate receptor. Antioxid Redox Signal. 2011 Jun;14(11):2165–2177.
121. M.Needham, F.L.Mastaglia. Sporadic inclusion body myositis:A review of recent clinical advances and current approaches to diagnosis and treatment. Clin Neurophysiol:off J Int Fed Clin Neurophysiol. 2016 Mar;127(3):1764–1773.
122. V.Askanas, W.K.Engel, A.Nogalska. Sporadic inclusion-body myositis:A degenerative muscle disease associated with aging, impaired muscle protein homeostasis and abnormal mitophagy. Biochim Biophys Acta. 2015 Apr;1852(4):633–643.
123. V.Askanas, W.K.Engel. Sporadic inclusion-body myositis:conformational multifactorial ageing-related degenerative muscle disease associated with proteasomal and lysosomal inhibition, endoplasmic reticulum stress, and accumulation of amyloid-beta42 oligomers and phosphorylated tau. Presse Medicale. 2011 Apr;40(4 Pt 2):e219–235.
124. M.Kusaczuk, M.Bartoszewicz, M.Cechowska-Pasko. Phenylbutyric acid:simple structure – multiple effects. Curr Pharm Des. 2015;21(16):2147–2166.
125. T.Iannitti, B.Palmieri. Clinical and experimental applications of sodium phenylbutyrate. Drugs in R&D. 2011 Sep 1;11(3):227–249.
126. L.W.Chen, L.Y.Horng, C.L.Wu, et al. Activating mitochondrial regulator PGC-1alpha expression by astrocytic NGF is a therapeutic strategy for Huntington’s disease. Neuropharmacology. 2012 Sep;63(4):719–732.
127. L.Knuppertz, H.D.Osiewacz. Orchestrating the network of molecular pathways affecting aging:role of nonselective autophagy and mitophagy. Mech Ageing Dev. 2016 Jan;153:30–40.
128. M.Larrosa, M.T.García-Conesa, J.C.Espín, et al. Ellagitannins, ellagic acid and vascular health. Mol Aspects Med. 2010 Dec;31(6):513–539.
129. J.Hyttel, J.J.Larsen. Neurochemical profile of Lu 19-005, a potent inhibitor of uptake of dopamine, noradrenaline, and serotonin. J Neurochem. 1985 May;44(5):1615–1622.
130. J.C.Heo, T.H.Jung, D.Y.Jung, et al. Indatraline inhibits Rho- and calcium-mediated glioblastoma cell motility and angiogenesis. Biochem Biophys Res Commun. 2014 Jan 10;443(2):749–755.
131. Hong Kong Baptist University, Hong Kong, HK. Usage of oblongifolin C, a natural comound from Garcinia Yunnanesis Hu, on treating cancer as metastasis inhibitor and autophagy flux inhibitor.US20140194530A1. 2014.
132. Translational Genomics Research Institute, Pheonix, AZ, US, Van Andel Research Institute, Grand Rapids, MI, US. Autophagy inhibitors.US20140148451A1. 2014.
133. Spectrum Pharmaceuticals Inc. Irvine, CA, US. Thioxanthone-based autophagy inhibitor therapies to treat cancer.US20140106003A1. 2014.
134. China Medical University, Taichung City, TW. Method for inhibiting autophagy of motor neurons.US20140045765A1. 2014.
135. Universitaet, Basel, CH. Combination of lysosomotropic or autophagy modulating agents and a GSK-3 inhibitor for treatment of cancer.WO2013182519A1. 2013.
136. L.Dassonneville, C.Bailly. Stimulation of topoisomerase II-mediated DNA cleavage by an indazole analogue of lucanthone. Biochem Pharmacol. 1999 Oct 15;58(8):1307–1312.
137. M.Luo, M.R.Kelley. Inhibition of the human apurinic/apyrimidinic endonuclease (APE1) repair activity and sensitization of breast cancer cells to DNA alkylating agents with lucanthone. Anticancer Res. 2004 Jul-Aug;24(4):2127–2134.
138. S.J.Kaur, S.R.McKeown, S.Rashid. Mutant SOD1 mediated pathogenesis of amyotrophic lateral sclerosis. Gene. 2016 Feb 15;577(2):109–118.
139. T.An, P.Shi, W.Duan, et al. Oxidative stress and autophagic alteration in brainstem of SOD1-G93A mouse model of ALS. Mol Neurobiol. 2014 Jun;49(3):1435–1448.
140. G.C.Higgins, R.J.Devenish, P.M.Beart, et al. Transitory phases of autophagic death and programmed necrosis during superoxide-induced neuronal cell death. Free Radic Biol Med. 2012 Nov 15;53(10):1960–1967.
141. M.Arfeen, P.V.Bharatam. Design of glycogen synthase kinase-3 inhibitors:an overview on recent advancements. Curr Pharm Des. 2013;19(26):4755–4775.
142. Salk Institute For Biological Studies, CA, US. Ulk1 compositions, inhibitors, screening and methods of use.US20130040310A1. 2013.
143. A.Md Pharma, S.E.Smith. Adenine derivatives suitable for the treatment of (inter alia) muscular dystrophy.WO2014083327A1. 2014.
144. D.J.Klionsky, K.Abdelmohsen, A.Abe, et al. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy. 2016 Jan 2;12(1):1–222.•• It is an excellent guideline for use and interpretation of autophagy assays in vitro and in vivo.
145. M.M.Lipinski, B.Zheng, T.Lu, et al. Genome-wide analysis reveals mechanisms modulating autophagy in normal brain aging and in Alzheimer’s disease. Proc Natl Acad Sci U S A. 2010 Aug 10;107(32):14164–14169.• This study provides the biochemical evidence showing that autophagy is upregulated in Alzheimer’s disease, whereas autophagy in brain is normally decreased upon aging. Since autophagy contributes to amyloid-β formation and, simultaneously, it is required for the clearance of this toxic protein aggregate, this study suggests that inhibiting autophagy at an early stage and/or enhancing autolysosome formation may be desirable to treat Alzheimer’s disease.
146. H.Weidberg, E.Shvets, Z.Elazar. Biogenesis and cargo selectivity of autophagosomes. Annu Rev Biochem. 2011;80:125–156.
147. J.Y.Lee, H.Koga, Y.Kawaguchi, et al. HDAC6 controls autophagosome maturation essential for ubiquitin-selective quality-control autophagy. EMBO J. 2010 Mar 3;29(5):969–980.
148. E.Y.Liu, K.M.Ryan. Autophagy and cancer – issues we need to digest. J Cell Sci. 2012 May 15;125(Pt 10):2349–2358.
149. K.Sasaki, N.H.Tsuno, E.Sunami, et al. Chloroquine potentiates the anti-cancer effect of 5-fluorouracil on colon cancer cells. BMC Cancer. 2010;10:370.
150. E.Briceño, A.Calderon, J.Sotelo. Institutional experience with chloroquine as an adjuvant to the therapy for glioblastoma multiforme. Surg Neurol. 2007 Apr;67(4):388–391.
151. R.Rangwala, R.Leone, Y.C.Chang, et al. Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma. Autophagy. 2014 Aug;10(8):1369–1379.
152. R.Rangwala, Y.C.Chang, J.Hu, et al. Combined MTOR and autophagy inhibition:phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma. Autophagy. 2014 Aug;10(8):1391–1402.
153. R.K.Amaravadi, J.Winkler. Novel bisaminoquinoline compounds, pharmaceutical compositions prepared therefrom and their use.20140050696. 2014.
154. W.David, A.K.Speicher, R.K.Amaravadi. Methods and compositions employing secreted proteins that reflect autophagy dynamics within tumor cells.20150233930. 2015.
155. N.Mujumdar, A.K.Saluja. Autophagy in pancreatic cancer:an emerging mechanism of cell death. Autophagy. 2010 Oct;6(7):997–998.
156. H.Takeuchi, Y.Kondo, K.Fujiwara, et al. Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors. Cancer Res. 2005 Apr 15;65(8):3336–3346.
157. A.Iwamaru, Y.Kondo, E.Iwado, et al. Silencing mammalian target of rapamycin signaling by small interfering RNA enhances rapamycin-induced autophagy in malignant glioma cells. Oncogene. 2007 Mar 22;26(13):1840–1851.
158. C.Cao, T.Subhawong, J.M.Albert, et al. Inhibition of mammalian target of rapamycin or apoptotic pathway induces autophagy and radiosensitizes PTEN null prostate cancer cells. Cancer Res. 2006 Oct 15;66(20):10040–10047.